Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2019-04-30 07:00:21
Oslo, Norway, 30 April 2019 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, will announce its first quarter 2019 results on Thursday, 9 May 2019. A presentation by Targovax's management to investors, analysts and the press will take place in Oslo at 10:00 CET. The results report and the presentation will be available at www.targovax.com in the Investors section from 07:00 CET. Presentation The presentation will take place at 10:00 CET at: Hotel Continental Stortingsgaten 24/26 0117 Oslo. The presentation will also be webcast live (http://webtv.hegnar.no/presentation.php?webcastId=97815727) and can be accessed through www.targovax.com (https://www.targovax.com/en/event/q1-2019 -targovax-quarterly-results/). For further information, please contact: Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com Media and IR enquires: Andreas Tinglum - Corporate Communications (Norway) Phone: +47 9300 1773 Email: andreas.tinglum@corpcom.no (Targovax@fticonsulting.com) About Targovax Activating the patient's immune system to fight cancer Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine. Targovax's lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It has been shown to activate the immune system to generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced both local and systemic innate and adaptive immune activation, which has been associated with clinical benefit. ONCOS-102's targeted path-to-market indication is mesothelioma, where the virus is currently being tested in a randomized phase II trial. Another trial, in checkpoint inhibitor refractory advanced melanoma, is expected to produce important proof-of-concept immune activation data in heavily pre-treated patients. Targovax is also developing a neoantigen cancer vaccine targeting tumors with oncogenic RAS-mutations, which are known to drive cancer. The TG vaccine program has shown strong RAS-specific immune activation and a signal of clinical efficacy in a 32-patient trial with TG01 in resected pancreatic cancer. A next generation product candidate, TG02 is currently tested in a phase I trial in colorectal cancer, both as monotherapy and in combination with Keytruda (an anti -PD1 check point inhibitor).